RECRUITING Phase 2 ClinicalTrials.gov

Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study

Sponsor: City of Hope Medical Center • ClinicalTrials.gov ID: NCT06052826

Registry updated: 2026-09-25

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This clinical trial compares the effectiveness of geriatric assessment (GA) guided interventions to accelerate functional recovery after chimeric antigen receptor T-cell (CAR-T) therapy compared to standard of care (SOC) in patients 60 years and older with B-cell non-Hodgkin lymphoma (NHL) or multiple myeloma (MM). A large number of patients diagnosed with cancer are over the age of 60, yet most cancer treatments are developed for younger patients. Therefore, older patients may be less likely to be offered stronger treatments, such as CAR-T therapy, due to possible side effects. Geriatric assessment is a multi-dimensional health assessment tool combining patient reported and objective measures covering physical function, mental processes (cognitive), and nutrition. Pre-treatment assessments may identify weaknesses in older adults and may guide interventions for physical therapy, cognitive changes and nutrition to decrease CAR-T therapy side effects and improve care in older adults with NHL or MM.

Interventions

Best Practice (Other)
Undergo standard of care
Cognitive Intervention (Other)
Receive delirium prevention education
Comprehensive Geriatric Assessment (Other)
Undergo geriatric assessment
Nutritional Intervention (Other)
Undergo nutritional optimization
Physical Therapy (Procedure)
Undergo physical function optimization
Questionnaire Administration (Other)
Ancillary studies

Eligibility criteria

Inclusion Criteria: * Ability to provide informed consent * Patient's physician must agree for patient participation. A physician may elect to provide blanket agreement for participation of any eligible CAR-T patient under their care * Ability to read English, or Spanish. Other languages will be acceptable with site principal investigator (PI) agreement if surveys are available and language does not preclude completing study procedures * Age: \>= 60 years at the time of enrollment * Scheduled to receive an Food and Drug Administration (FDA)-approved CAR-T for treatment of multiple myeloma or B-cell non- Hodgkin lymphoma * Willing and able to complete study requirements * Patients expect to be able to participate at least once before lymphodepletion with trimodality optimization visits Exclusion Criteria: * Prior CAR-T therapy * Any condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures * Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

Conditions

B-Cell Non-Hodgkin Lymphoma Multiple Myeloma

Locations

City of Hope Medical Center — Duarte, California, United States
City of Hope at Irvine Lennar — Irvine, California, United States
Wake Forest University, School of Medicine Dept. of Internal Medicine, Division of Hematology Oncology — Winston-Salem, North Carolina, United States
Ohio State University Medical Center Dept. of Internal Medicine, Division of Hematology — Columbus, Ohio, United States

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment